-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113

Benzinga·10/27/2026 10:46:53
Listen to the news
Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.